Zacks Investment Research·Jun 26, 2026
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerIndivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Marker Therapeutics, Inc.(MRKR)Earnings, Financials & Key Ratios
MRKR•NASDAQ
$1.47
Price updated Jun 30, 2026
AboutMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.Show more
- Revenue$0-100.0%
- EBITDA-$12M-11.9%
- Net Income-$12M-13.3%
- EPS (Diluted)-0.79+33.6%
- ROE-0%+100.0%
MRKR Price & Volume
Marker Therapeutics, Inc. (MRKR) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pipeline Development Drives Persistent Capital Erosion
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Dependency
Key Thesis Takeaways
- Marker Therapeutics is currently navigating a high-risk transition as it pivots entirely toward its proprietary MultiTAA cell therapy platform, resulting in a complete loss of commercial revenue as of 2026Q1.
- The company's financial stability remains heavily dependent on external equity financing to sustain R&D expenditures that consistently exceed $2 million per quarter.
- Investors should monitor the firm's ability to advance its MT-601 and MT-401 programs, as the current trajectory of accumulated deficits reaching -$462.4 million underscores the significant capital intensity required to reach potential commercialization.
Verdict Logic
the company's lack of commercial revenue and the consistent depletion of its $14.9 million cash balance as of 2026Q1 present substantial risks to long-term equity value.
MRKR Growth Metrics
Marker Therapeutics, Inc. (MRKR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-63.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM49.62%
Return on Capital
10 Years-122.53%
5 Years-54.36%
3 Years-46.62%
Last Year-0%
MRKR Recent Earnings
Marker Therapeutics, Inc. (MRKR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 6/12 qtrs (100%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.16+11.1%
$0.18
Rev
—
$682,100
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.04+81.0%
$0.21
Rev
$1M+61.3%
$682,100
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.12+66.7%
$0.36
Rev
$1M+70.5%
$723,000
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.29+4.6%
$0.30
Rev
$861,184+100.0%
$430,600
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.16vs $0.18+11.1% | —vs $682,100 |
| Q2 2026 | Mar 18, 2026 | $0.04vs $0.21+81.0% | $1Mvs $682,100+61.3% |
| Q4 2025 | Nov 13, 2025 | $0.12vs $0.36+66.7% | $1Mvs $723,000+70.5% |
| Q3 2025 | Aug 14, 2025 | $0.29vs $0.30+4.6% | $861,184vs $430,600+100.0% |
Based on last 12 quarters of dataView full earnings history →
Latest MRKR News
Recent stock market news and headlines for Marker Therapeutics, Inc. (MRKR)
Zacks Investment Research·Jun 25, 2026
5 Small Drug Stocks to Invest in Amid a Biotech ComebackInnovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Peers Comparison
Key metrics vs top competitors for Marker Therapeutics, Inc. (MRKR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.47 | $15.87M | -1.86 | -100% | — | -0% | — | |
| $2.70 | $314.71M | -2.35 | -51.24% | -2056.79% | -58.89% | — | |
| $3.06 | $127.43M | -900.00 | 10.37% | 52.16% | — | — | |
| $1.07 | $136.09M | -0.96 | 14.85% | -173.02% | — | — | |
| $38.53 | $7.91B | -13.91 | — | — | -68.16% | — | |
| $3.11 | $507.1M | -1.90 | — | — | -131.58% | — |
Compare MRKR vs Peers
Marker Therapeutics, Inc. (MRKR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MRKR SEC Filings & Documents
Marker Therapeutics, Inc. (MRKR) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Feb 9, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when MRKR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MRKR Frequently Asked Questions
Marker Therapeutics, Inc. (MRKR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Marker Therapeutics, Inc.'s revenue?
Marker Therapeutics, Inc. (MRKR) reported $2.1M in revenue for fiscal year 2025. This represents a 1635% increase from $0.1M in 1999.
How fast is Marker Therapeutics, Inc. growing?
Marker Therapeutics, Inc. (MRKR) saw revenue decline by 100.0% over the past year.
Is MRKR profitable?
Marker Therapeutics, Inc. (MRKR) reported a net loss of $10.9M for fiscal year 2025.
Dividend & Returns
What is MRKR's return on equity?
Marker Therapeutics, Inc. (MRKR) has a return on equity (ROE) of -0.0%. Negative ROE indicates the company is unprofitable.
What is Marker Therapeutics, Inc.'s free cash flow?
Marker Therapeutics, Inc. (MRKR) had negative free cash flow of $7.9M in fiscal year 2025, likely due to heavy capital investments.